Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection McGovern BH; Abu Dayyeh BK; Chung RTHepatology 2008[Nov]; 48 (5): 1700-12The development of specifically targeted antiviral agents against hepatitis C is a major therapeutic advance that promises to markedly improve treatment response rates in patients with chronic infection. However, rapid emergence of drug resistance has already been described, the consequences of which are not yet understood. Although there are important differences between hepatitis C (HCV) and human immunodeficiency virus (HIV) infection, the judicious use of candidate agents against HCV should be guided by principles that have been established in the HIV therapeutic arena. In this review, we attempt to draw useful parallels between the development of antiretroviral therapy for HIV and preliminary data on antiviral agents for hepatitis C virus infection. Applying concepts learned in HIV therapeutics will hopefully lead to a prudent and cautious path in HCV treatment paradigms, particularly with respect to drug resistance.|Antiviral Agents/adverse effects/*therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Cyclophilins/antagonists & inhibitors[MESH]|Hepatitis C/*drug therapy[MESH]|Humans[MESH]|Interferon alpha-2[MESH]|Interferon-alpha/adverse effects/therapeutic use[MESH]|Polyethylene Glycols/adverse effects/therapeutic use[MESH]|Protease Inhibitors/adverse effects/therapeutic use[MESH]|Recombinant Proteins[MESH]|Treatment Failure[MESH]|Treatment Outcome[MESH] |